Recent controversy about access and IP Will India risk the wrath of many of its trading partners by issuing more compulsory licences to give access to innovative medicines? The question has flared to life again over the past few weeks. In early March, US trade groups sounded triumphal: India had assured the Americans that it would respect the … [Read more...] about What India will really do about access to innovative medicines
Hyderus Cyf and Hyderus Teoranta
Videos
The Three Commitments
Why Consultants end up not telling the truth
The worst kind of market research interviewing technique ever
Why bright people can’t explain themselves
Clients
